After 21 days post-intracranial transplantation of DFBM-Ni17/tetp16INK4A BCBM tumor cells, these recipient mice were provided with doxycycline diet (dox) to induce p16INK4A expression and started receiving tucatinib treatment. The gene discussed is CDKN2A; the disease is neoplasm.